Jean-Pierre Pouget

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1701568/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Hydroxyl radicals and DNA base damage. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 424, 9-21. | 0.4 | 544 |
| 2 | High-Performance Liquid Chromatographyâ^'Tandem Mass Spectrometry Measurement of Radiation-Induced Base Damage to Isolated and Cellular DNA. Chemical Research in Toxicology, 2000, 13, 1002-1010. | 1.7 | 277 |
| 3 | Clinical radioimmunotherapy—the role of radiobiology. Nature Reviews Clinical Oncology, 2011, 8, 720-734. | 12.5 | 191 |
| 4 | The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond. Frontiers in Oncology, 2014, 3, 324. | 1.3 | 142 |
| 5 | Introduction to Radiobiology of Targeted Radionuclide Therapy. Frontiers in Medicine, 2015, 2, 12. | 1.2 | 131 |
| 6 | Facts and artifacts in the measurement of oxidative base damage to DNA. Free Radical Research, 1998, 29, 541-550. | 1.5 | 125 |
| 7 | General aspects of the cellular response to low- and high-LET radiation. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 541-561. | 2.2 | 121 |
| 8 | Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis. Antioxidants and Redox Signaling, 2018, 29, 1447-1487. | 2.5 | 104 |
| 9 | Assessment of oxidative base damage to isolated and cellular DNA by HPLC-MS/MS measurement1,2 1This article is part of a series of reviews on "Oxidative DNA Damage and Repair.―The full list of papers may be found on the homepage of the journal. 2Guest Editor: Miral Dizdaroglu. Free Radical Biology and Medicine, 2002, 33, 441-449. | 1.3 | 99 |
| 10 | Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons. Radiation Research, 2008, 170, 192-200. | 0.7 | 99 |
| 11 | Radiation-Induced DNA Damage: Formation, Measurement, and Biochemical Features. Journal of Environmental Pathology, Toxicology and Oncology, 2004, 23, 33-44. | 0.6 | 96 |
| 12 | Minor contribution of direct ionization to DNA base damage inducedby heavy ions. International Journal of Radiation Biology, 2006, 82, 119-127. | 1.0 | 93 |
| 13 | [14] Singlet oxygen DNA damage products: Formation and measurement. Methods in Enzymology, 2000, 319, 143-153. | 0.4 | 86 |
| 14 | Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxidants and Redox Signaling, 2016, 25, 467-484. | 2.5 | 68 |
| 15 | Place of 18F-FDG-PET with computed tomography in the diagnostic algorithm of patients with fever of unknown origin. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1727-1733. | 1.3 | 63 |
| 16 | Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. , 2019, 7, 29. | | 63 |
| 17 | Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 1251 Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis. Journal of Nuclear Medicine, 2009, 50, 2033-2041. | 2.8 | 58 |
| 18 | Revisiting the Radiobiology of Targeted Alpha Therapy. Frontiers in Medicine, 2021, 8, 692436. | 1.2 | 54 |

2

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb. PLoS ONE, 2013, 8, e69613. | 1.1 | 54 |
| 20 | General overview of radioimmunotherapy of solid tumors. Immunotherapy, 2013, 5, 467-487. | 1.0 | 39 |
| 21 | Comparison of commercial dosimetric software platforms in patients treated with ¹⁷⁷ Luâ€DOTATATE for peptide receptor radionuclide therapy. Medical Physics, 2020, 47, 4602-4615. | 1.6 | 34 |
| 22 | Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Research, 2018, 8, 103. | 1.1 | 31 |
| 23 | Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway. Frontiers in Immunology, 2021, 12, 680503. | 2.2 | 31 |
| 24 | Modulation of DNA Damage by Pentoxifylline and α-Tocopherol in Skin Fibroblasts Exposed to Gamma Rays. Radiation Research, 2005, 164, 63-72. | 0.7 | 30 |
| 25 | DNA damage in cultured skin microvascular endothelial cells exposed to gamma rays and treated by the combination pentoxifylline and α-tocopherol. International Journal of Radiation Biology, 2006, 82, 309-321. | 1.0 | 30 |
| 26 | Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0128816. | 1.1 | 30 |
| 27 | Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane. Nuclear Medicine and Biology, 2013, 40, 471-480. | 0.3 | 28 |
| 28 | Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Medical Physics, 2013, 40, 052501. | 1.6 | 26 |
| 29 | The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. MAbs, 2014, 6, 1314-1326. | 2.6 | 26 |
| 30 | Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clinical Cancer Research, 2019, 25, 4775-4790. | 3.2 | 26 |
| 31 | Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models. Scientific Reports, 2017, 7, 14918. | 1.6 | 25 |
| 32 | Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer. Oncotarget, 2017, 8, 22034-22047. | 0.8 | 25 |
| 33 | DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy. Nuclear Medicine and Biology, 2014, 41, e75-e83. | 0.3 | 24 |
| 34 | Modulation of exogenous and endogenous levels of thioredoxin in human skin fibroblasts prevents DNA damaging effect of ultraviolet A radiation. Free Radical Biology and Medicine, 2001, 30, 537-546. | 1.3 | 23 |
| 35 | Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵ I-Labeled Monoclonal Antibodies. Journal of Nuclear Medicine, 2010, 51, 1748-1755. | 2.8 | 23 |
| 36 | Glucose metabolism in nine patients with probable sporadic Creutzfeldt–Jakob disease: FDG-PET study using SPM and individual patient analysis. Journal of Neurology, 2013, 260, 3055-3064. | 1.8 | 23 |

JEAN-PIERRE POUGET

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept. Theranostics, 2019, 9, 6706-6718. | 4.6 | 23 |
| 38 | Call to arms: need for radiobiology in molecular radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1588-1590. | 3.3 | 23 |
| 39 | Peptides in Receptor-Mediated Radiotherapy: From Design to the Clinical Application in Cancers. Frontiers in Oncology, 2013, 3, 247. | 1.3 | 20 |
| 40 | Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Research, 2011, 13, R17. | 2.2 | 19 |
| 41 | The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget, 2017, 8, 37061-37079. | 0.8 | 16 |
| 42 | Realistic multi-cellular dosimetry for ¹⁷⁷ Lu-labelled antibodies: model and application. Physics in Medicine and Biology, 2016, 61, 6935-6952. | 1.6 | 15 |
| 43 | Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. Journal of Nuclear Medicine, 2018, 59, 1234-1242. | 2.8 | 15 |
| 44 | Therapeutic antibodies $\hat{a} \in$ " natural and pathological barriers and strategies to overcome them. , 2022, 233, 108022. | | 15 |
| 45 | Radiocurability by Targeting Tumor Necrosis Factor-α Using a Bispecific Antibody in Carcinoembryonic Antigen Transgenic Mice. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1231-1237. | 0.4 | 14 |
| 46 | Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. Pharmaceutics, 2021, 13, 980. | 2.0 | 14 |
| 47 | From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience. Nuclear Medicine and Biology, 2022, 104-105, 53-64. | 0.3 | 14 |
| 48 | Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma. Investigational New Drugs, 2014, 32, 587-597. | 1.2 | 12 |
| 49 | The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia, 2020, 34, 1315-1328. | 3.3 | 12 |
| 50 | Assessment of the Stratos, a New Pencil-Beam Bone Densitometer: Dosimetry, Precision, and Cross Calibration. Journal of Clinical Densitometry, 2011, 14, 395-406. | 0.5 | 11 |
| 51 | Complex cell geometry and sources distribution model for Monte Carlo single cell dosimetry with iodine 125 radioimmunotherapy. Nuclear Instruments & Methods in Physics Research B, 2016, 366, 227-233. | 0.6 | 11 |
| 52 | In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8. BMC Neurology, 2016, 16, 100. | 0.8 | 7 |
| 53 | Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127527. | 1.0 | 7 |
| 54 | Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy. International Journal of Radiation Biology, 2023, 99, 109-118. | 1.0 | 6 |

JEAN-PIERRE POUGET

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Immunostimulatory effects of radioimmunotherapy. , 2022, 10, e004403. | | 5 |
| 56 | Tandem myeloablative1311-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy, 2013, 5, 1283-1286. | 1.0 | 3 |
| 57 | 18th European Symposium on Radiopharmacy and Radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 2016, 1, . | 1.8 | 2 |
| 58 | Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study. Clinical Nutrition, 2019, 38, 2121-2126. | 2.3 | 2 |
| 59 | Status of radiobiology in molecular radionuclide therapy – Hope for the future. Nuclear Medicine and Biology, 2022, 110-111, 45-46. | 0.3 | 1 |
| 60 | Basics of radiobiology. , 2022, , . | | 0 |
| 61 | Radiobiology of Targeted Alpha Therapy. , 2022, , 380-403. | | 0 |